Gilead Raises 2020 Profit Outlook on Remdesivir Demand


Gilead Sciences Inc. expects sales of its Covid-19 drug remdesivir to help lift its full-year revenue by as much as $2.8 billion in 2020, offsetting the negative impact of the pandemic on some of its other medicines.

The biopharmaceutical company began selling remdesivir, an antiviral drug shown to help speed recovery times in hospitalized Covd-19 patients, in July. It said Thursday it expects to sell one million to 1.5 million treatment courses in the second half of the year.

Source link